FDA approves next-generation stem cell therapy for cancer, while research advances across rosacea treatment, breast cancer outcomes, and inflammatory conditions.

FDA has approved Orca-T, a next-generation hematopoietic stem cell transplant (HSCT) therapy that reduces graft-versus-host disease (GVHD) in adults with hematologic cancers by carefully controlling the mix of stem and T cells.

Topical ivermectin and encapsulated benzoyl peroxide have demonstrated superior efficacy compared to metronidazole in treating moderate-to-severe rosacea, improving both inflammatory lesions and overall disease severity.

Asian women diagnosed with breast cancer show significantly better survival outcomes compared to their white peers, prompting researchers to investigate biological and clinical factors contributing to these disparities.

Dermatologists are addressing widespread misinformation on social media about sun exposure and alternative tanning methods, with concerns about influencer-driven UV safety misconceptions affecting public health.

Electronic health record (EHR) burden remains a significant source of physician burnout, with solutions focusing on automation of routine administrative tasks rather than incremental workflow improvements to preserve clinical focus.

Proton therapy for prostate cancer outcomes are primarily determined by treatment quality and multidisciplinary program execution rather than the radiation modality itself, according to clinical analysis.

Food preservative associations with cancer appear statistically significant but carry minimal absolute risk, with only a 1-1.5% increase in cancer risk by age 60, requiring appropriate clinical contextualization.

A substantial proportion of giant cell arteritis (GCA) patients have undetected subclinical polymyalgia rheumatica, indicating these conditions frequently coexist with distinct disease patterns requiring comprehensive evaluation.